Washington, DC 20549
(RULE 14a-101)
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.  ___   )
Filed by the Registrant                             Filed by a Party other than the Registrant
Check the appropriate box:
Preliminary Proxy Statement.
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)).
Definitive Proxy Statement.
Definitive Additional Materials.
Soliciting Material Pursuant to §240.14a-12.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
Title of each class of securities to which transaction applies:
Aggregate number of securities to which transaction applies:
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
Proposed maximum aggregate value of transaction:
Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
Amount Previously Paid:
Form, Schedule or Registration Statement No.:
Filing Party:
Date Filed:
1430 US-206 #200,
Township, NJ
  August 1, 2017
Dear CRMD Stockholder,
According to our latest records, we have not received your voting instructions for the reconvened Special Meeting of Stockholders CorMedix Inc., to be held on Tuesday, August 8th. Your vote is extremely important, no matter how many shares you hold.
For the reasons set forth in the proxy statement, dated June 29, 2017, found at the Investors tab on CRMD’s website located at, your Board of Directors recommends that you vote “FOR” Proposal No. 1. As discussed in the proxy statement, we believe the stock issuance increase amount (and the accompanying proposal) is sufficient for our most pressing need, which is continuing the LOCK IT 100 trial through the completion of patient enrollment. Further, we believe that the current requested increase in authorized shares is in line with increases sought by other comparable public pharmaceutical companies. Please vote via the internet or phone as soon as possible or alternatively, please sign, date, and return the enclosed proxy card.
The results of the voting so far have indicated the clear majority of shares that have been voted to date have voted to approve Proposal 1. Your vote is requested to ensure that the proposal is approved by the majority of the shares outstanding.
The record date for determining stockholders eligible to vote at the special meeting will remain the close of business on June 23, 2017.
If you need assistance voting your CRMD shares, please call D.F. King toll-free at (800) 283-3192 or collect at (212) 269-5550. On behalf of your Board of Directors, thank you for your cooperation and continued support.
Antony E. Pfaffle, M.D.,
Chief Scientific Officer & Secretary
Vote Online – Please have your control number listed on the enclosed proxy card or voting instruction form ready and follow the online instructions at
Vote by Phone – Please have the control number listed on the enclosed proxy card or voting instruction form ready and call (800) 690-6903.
Vote by Mail by completing, signing and dating the enclosed voting instruction form and returning it in the pre-paid envelope provided in this package.